Press releases

Filter by year

  • Dec 20, 2021
    Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Sy…
  • Nov 08, 2021
    Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTES…
  • Oct 18, 2021
    Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion
  • Sep 13, 2021
    Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was…
  • Sep 03, 2021
    Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bla…
  • Aug 18, 2021
    Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bla…
  • Aug 12, 2021
    Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer
  • Jul 06, 2021
    Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
  • Jun 29, 2021
    Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive…
  • Apr 15, 2021
    Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Blad…
  • Apr 12, 2021
    Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
  • Feb 12, 2021
    Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
  • Feb 11, 2021
    Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monito…